Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease

European Heart Journal

Volumn 24, Issue 5, 2003, Pages 475-484

  Chaturvedi, V ^a   Patel, A ^a   Chalmers, John ^a   Chapman, N ^a   Hansson, L ^a   MacMahon, S ^a   Mancia, G ^a   Neal, B ^a   Reid, J ^a   Sharpe, N ^a   Woodward, M ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

ACE inhibitor; Blood pressure; Congestive heart failure; Coronaryheart disease; Diuretic; Indapamide; Perindopril; Randomised trial

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; PERINDOPRIL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CEREBROVASCULAR DISORDERS; CORONARY DISEASE; DEATH, SUDDEN, CARDIAC; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PERINDOPRIL; RISK FACTORS; TREATMENT OUTCOME;

EID: 0037337368     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00804-7     Document Type: Article

References (29)

1. Collins R, Peto R, MacMahon S et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-39.
2. Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50:272-98.
3. Moser M, Hebert P. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27:1214-8.
4. Flather M, Yusuf S, Kober L et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-81.
5. Shibata M, Flather M, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351-7.
6. ACE inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100 000 patients in randomized trials. Circulation 1998;97:2202-12.
7. Yusuf S, Peto R, Lewis J et al. Beta-blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
8. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet 2000; 356:1955-64.
9. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. J Hypertens 1996;14(suppl 2):S41-6.
10. Hartmann A, Rundek T, Mast H et al. Mortality and causes of death after first ischaemic stroke: the Northern Manhattan Stroke Study. Neurology 2001; 57:2000-5.
11. Bronnum-Hansen H, Davidsen M, Thorvaldsen P, for the Danish MONICA Study Group. Long-term survival and causes of death after stroke. Stroke 2001;32:2131-6.
12. Kelly R, Staines A, MacWalter R et al. The prevalence of treatable left ventricular systolic dysfunction in patients who present with noncardiac vascular episodes: a casecontrol study. J Am Coll Cardiol 2002;39:219-24.
13. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335:765-74.
14. van den Hoogen P, Feskens E, Nagelkerke N et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. Seven Countries Study Research Group. N Engl J Med 2000;342:1-8.
15. Flack J, Neaton J, Grimm R et al. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995;92:2437-45.
16. Rodgers A, MacMahon S, Gamble G et al., on behalf of the UKTIA Collaborative Group. Blood pressure and risk of stroke in patients with cerebrovascular disease. Br Med J 1996; 313:147.
17. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-53.
18. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double blind randomised trial. Br Med J 2002; 324:1-5.
19. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
20. Woodward M. Epidemiology, study design and data analysis. Boca Raton: Chapman and Hall/CRC, 1999.
21. PROGRESS Management Committee. PROGRESS (Perindopril Protection Against Recurrent Stroke Study). Characteristics of the study population at baseline. J Hypertens 1999; 17:1647-55.
22. Yusuf S, Pepine CJ, Carces C et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992;340:1173-8.
23. Lonn EM, Yusuf S, Jha P et al. Emerging role of angiotensinconverting enzyme inhibitors in cardiac and vascular protection. Circulation 1994;90:2056-67.
24. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273:1450-6.
25. Flather M, Lonn E, Yusuf S. Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction: evidence from the larger randomized controlled trials. J Cardiovasc Risk 1995;2:423-8.
26. Dahlof B, Devereux R, Kjeldsen S et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003.
27. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Protocol for prospective collaborative overviews of major randomized trials of blood-pressure lowering treatments. J Hypertens 1998; 16:127-37.
28. Davis B, Cutler J, Gordon D et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996;9:342-60.
29. Fox K, Henderson J, Bertrand M et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J 1998; 19(Suppl J):J52-5.